£89.1M
The round was led by SoftBank Vision Fund 2 and will fund international expansion and product growth.
"We believe DICE’s technology has the capacity to transform the future of live entertainment,"
.png)
SoftBank Vision Fund 2
Venture CapitalSoftBank Vision Fund 2 supports disruptive business models and innovative technologies.
Recent investments
.png)
£94.0M
SoftBank Vision Fund 2 led the Series B financing to fund international growth and new product development.
"We are delighted to have reached such a significant milestone in our funding journey. This transaction will allow us to continue our leadership in data-driven specialty (re)insurance underwriting and will be transformational for our business reach and activity. For the first time Envelop Risk will be able to assume positions in risk capital, which gives us greater alignment with our partners. We are all really excited to work with SoftBank Investment Advisers and together meet the huge opportunities that we see present in emerging and complex risk underwriting."
£54.4M
The Manchester-based enterprise software company has raised £54.4m from SoftBank Vision Fund 2 and existing backers to scale its decision intelligence platform.
"We’re proud to be working with some of the biggest brands in the world. Modern businesses are complex and operate in an ever-changing world. It’s becoming impossible to run them without AI, which is enabling them to make consistently great decisions, faster and more accurately than ever before."
£600M
SoftBank Vision Fund 2 and Tiger Global backed the Series E financing, which values the business at £33bn.
"SoftBank and Tiger Global’s investments are an endorsement of our mission to create a global financial superapp that enables customers to manage all their financial needs through a single platform. This funding round makes Revolut the UK’s most valuable fintech, demonstrating investors’ confidence that we can deliver products that raise the bar for customers’ expectations across the whole financial services industry."
£425M
The funding round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group to support international expansion and technological development.
"This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals. This major injection of capital that now values us at $3billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion. As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem. I would also like to thank our existing investors for their long-term support."